A phase 1/2 trial of OH2+BS006 in advanced solid tumours, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.
OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07382531 by Binhui Biopharmaceutical Co., Ltd., with 30 participants planned, started 2023-09-07 and due to reach its primary completion in 2027-12-31. Interventions recorded: OH2+BS006.
Shares Binhui Biopharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Binhui Biopharmaceutical and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.